Immunology & Rheumatology Clinical Trials

Statistical methods in immunology & rheumatology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All immunology & rheumatology trials

1,062 results

• CACD1Independent statistical analysis of Cardiovascular Risk Stratification in Young People With Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05283538).Phase NAResults postedn = 91NCT05283538
• CAFETERIAIndependent statistical analysis of Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 73NCT03907397
• CAMMPSIndependent statistical analysis of Comprehensive vs. Assisted Management of Mood and Pain Symptoms: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01757301).Phase NAResults postedn = 296NCT01757301
• Campath-1H Induction to Allow Discontinuation of Calcineurin Inhibitors After Renal Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Campath-1H Induction to Allow Discontinuation of Calcineurin Inhibitors After Renal Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 40NCT00214201
• CAMPBELIndependent statistical analysis of CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 3NCT03591380
• Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?: Complete Statistical AnalysisIndependent statistical analysis of Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 40NCT00618332
• Can Transcranial Direct Current Stimulation Improve Ambulation and Fatigue Resistance in People With MS?: Complete Statistical AnalysisIndependent statistical analysis of Can Transcranial Direct Current Stimulation Improve Ambulation and Fatigue Resistance in People With MS?: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 14NCT02987621
• Cannabis for Spasticity in Multiple Sclerosis: Complete Statistical AnalysisIndependent statistical analysis of Cannabis for Spasticity in Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00682929).Phase 1/2Results postedn = 41NCT00682929
• CareConekta: A Smartphone App to Improve Engagement in HIV Care: Complete Statistical AnalysisIndependent statistical analysis of CareConekta: A Smartphone App to Improve Engagement in HIV Care: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03836625).Phase NAResults postedn = 200NCT03836625
• Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 45NCT01690143
• Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 53NCT01029054
• CATALYSTIndependent statistical analysis of A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 1/2Results postedn = 10NCT02545907
• Causes of Rotavirus Vaccine Failure in Zambian Children: Complete Statistical AnalysisIndependent statistical analysis of Causes of Rotavirus Vaccine Failure in Zambian Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01886833).Phase NAResults postedn = 420NCT01886833
• CC-5013 (Lenalidomide) and Rituximab in Waldenstrom’s Macroglobulinemia: Complete Statistical AnalysisIndependent statistical analysis of CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00142168).Phase 2Results postedn = 16NCT00142168
• CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 18NCT02424968
• CHAMPION 1Independent statistical analysis of A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 116NCT01677858
• CHAMPION 2Independent statistical analysis of A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1Results postedn = 22NCT01980589
• Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir: Complete Statistical AnalysisIndependent statistical analysis of Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 11NCT02097108
• Characteristics and Prevalence of Tuberculosis and HIV in Masiphumelele Township, Cape Town, South Africa: Complete Statistical AnalysisIndependent statistical analysis of Characteristics and Prevalence of Tuberculosis and HIV in Masiphumelele Township, Cape Town, South Africa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 1,250NCT00346476
• Characteristics of Pts Initiating Spiriva Respimat in Asthma: Complete Statistical AnalysisIndependent statistical analysis of Characteristics of Pts Initiating Spiriva Respimat in Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03692676).Phase NAResults postedn = 116,133NCT03692676
• CHASE 2Independent statistical analysis of A Study in Asthmatic Children (6 toPhase 2Results postedn = 54NCT01136655
• Check It! Positive Psychology Intervention to Improve Adherence in Adolescents With T1D: Complete Statistical AnalysisIndependent statistical analysis of Check It! Positive Psychology Intervention to Improve Adherence in Adolescents With T1D: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 120NCT02746627
• Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant: primary endpoint results,…Phase 1/2Results postedn = 35NCT03192397
• Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 11NCT01438177
• Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Osteoarthritis: Complete Statistical AnalysisIndependent statistical analysis of Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 160NCT05080660
• Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 175NCT00923013
• CLARITYIndependent statistical analysis of A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 1,326NCT00213135
• CLEAR 2Independent statistical analysis of Combining Lesinurad With Allopurinol in Inadequate Responders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01493531).Phase 3Results postedn = 610NCT01493531
• Clinical Assessment of a Closed-loop Insulin Delivery System: Complete Statistical AnalysisIndependent statistical analysis of Clinical Assessment of a Closed-loop Insulin Delivery System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01534013).Phase NAResults postedn = 23NCT01534013
• Clinical Assessment of a Closed-loop System With Glucagon, Exercise and Mixed Meals: Complete Statistical AnalysisIndependent statistical analysis of Clinical Assessment of a Closed-loop System With Glucagon, Exercise and Mixed Meals: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 24NCT02397265
• Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma: Complete Statistical AnalysisIndependent statistical analysis of Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02260492).Phase 1Results postedn = 879NCT02260492
• Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents: Complete Statistical AnalysisIndependent statistical analysis of Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01797562).Phase NAResults postedn = 116NCT01797562
• Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment: Complete Statistical AnalysisIndependent statistical analysis of Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00645164).Phase 1Results postedn = 59NCT00645164
• Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma: Complete Statistical AnalysisIndependent statistical analysis of Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 248NCT01436071
• Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 1/2Results postedn = 93NCT01471782
• Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03646123).Phase 2Results postedn = 255NCT03646123
• Clinical Trial of CNS-targeted HAART (CIT2): Complete Statistical AnalysisIndependent statistical analysis of Clinical Trial of CNS-targeted HAART (CIT2): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00624195).Phase 2/3Results postedn = 59NCT00624195
• Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients: Complete Statistical AnalysisIndependent statistical analysis of Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients: primary endpoint…Phase 4Results postedn = 19NCT03360682
• CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a): Complete Statistical AnalysisIndependent statistical analysis of CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a): primary endpoint results, effect estimate with confidence interval, sample-size…Phase 3Results postedn = 787NCT01010061
• Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin’s Lymphoma That Has Relapsed or Not Responded to Previous Treatment: Complete Statistical AnalysisIndependent statistical analysis of Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment: primary endpoint results, effect estimate with confidence interval,…Phase 1/2Results postedn = 29NCT00416351
• Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury: Complete Statistical AnalysisIndependent statistical analysis of Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00597818).Phase 2Results postedn = 121NCT00597818
• CoFAR7Independent statistical analysis of Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 92NCT01846208
• Cognitive Effects of Inhalational Versus Intravenous General Anesthesia in the Elderly: Complete Statistical AnalysisIndependent statistical analysis of Cognitive Effects of Inhalational Versus Intravenous General Anesthesia in the Elderly: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 200NCT00788008
• Cognitive Stimulation Therapy for Dementia: A Two-Armed Pragmatic Trial: Complete Statistical AnalysisIndependent statistical analysis of Cognitive Stimulation Therapy for Dementia: A Two-Armed Pragmatic Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05860127).Phase NAResults postedn = 133NCT05860127
• Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.: Complete Statistical AnalysisIndependent statistical analysis of Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 107NCT00390793
• Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt’s Lymphoma or Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 23NCT00133991
• Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 1,895NCT00408005
• Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL: Complete Statistical AnalysisIndependent statistical analysis of Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 22NCT02557516
• Combination Therapy for Atopic Dermatitis: Complete Statistical AnalysisIndependent statistical analysis of Combination Therapy for Atopic Dermatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00119158).Phase 4Results postedn = 90NCT00119158
• Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size…Phase NAResults postedn = 52NCT00594815

← All therapeutic areas